Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Syed Masood

Internal Medicine Raleigh, NC Medical Doctor

NPI 1053363325 CMS profile 2675

3214 Charles B Root Wynd, Suite 211, Raleigh, NC 27612

Open in the dashboard

General payments

$9,267

458 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Syed Masood of Raleigh, NC is reported in the CMS Open Payments database as having received $9,267 across 458 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,591 64
2024 General $1,291 61
2023 General $1,197 63
2022 General $1,164 57
2021 General $1,193 66
2020 General $1,049 62
2019 General $1,783 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Syed Masood
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Syed Masood were reported at $1,591. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Syed Masood Internal Medicine median Middle half National median
2019 $1,783 $159 $48–$570 $163
2020 $1,049 $119 $33–$402 $114
2021 $1,193 $135 $37–$521 $132
2022 $1,164 $141 $42–$496 $149
2023 $1,197 $149 $45–$519 $160
2024 $1,291 $154 $47–$537 $164
2025 $1,591 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ViiV Healthcare Company $2,965 176 payments
  2. AstraZeneca Pharmaceuticals LP $967 25 payments
  3. GlaxoSmithKline, LLC. $607 24 payments
  4. Merck Sharp & Dohme Corporation $564 37 payments
  5. Gilead Sciences, Inc. $491 26 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $423 25 payments
  7. Mylan Specialty L.P. $398 17 payments
  8. Paratek Pharmaceuticals, Inc. $390 20 payments
  9. Janssen Products, LP $315 4 payments
  10. Genzyme Corporation $310 15 payments
  11. Other $1,836 89 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,919 453 payments
  2. Education $348 5 payments
Products named General payments · program years 2019–2025
  1. DOVATO $2,042 122 payments
  2. SYMTUZA $454 12 payments
  3. TRELEGY ELLIPTA $412 13 payments
  4. PIFELTRO $406 26 payments
  5. FASENRA $403 5 payments
  6. NUZYRA $390 20 payments
  7. DELSTRIGO $377 25 payments
  8. DUPIXENT $310 15 payments
  9. AIRSUPRA $305 6 payments
  10. LONHALA MAGNAIR $298 14 payments
  11. Other $5,282 292 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

1,314

Median for Internal Medicine: 777

Drug cost

$894,977

Median for Internal Medicine: $73,373

Branded share of claims

28.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 95 $424,912
Rukobia Fostemsavir Tromethamine Brand 14 $145,315
Dovato Dolutegravir Sodium/Lamivudine Brand 32 $102,790
Tivicay Dolutegravir Sodium Brand 31 $74,976
Prezcobix Darunavir/Cobicistat Brand 21 $50,800
Isentress Raltegravir Potassium Brand 16 $31,375
Descovy Emtricitabine/Tenofov Alafenam Brand 12 $30,245
Eliquis Apixaban Brand 12 $7,353
Savella Milnacipran Hcl Brand 12 $6,218
Doxycycline Hyclate Generic 73 $5,718

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$24,470

Medicare's payments for the services billed

Medicare patients

133

Average age 76

Services billed

246

71 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Chronic kidney disease 39%
Ischemic heart disease 35%
Atrial fibrillation 32%
Depression 32%
Diabetes 31%
Heart failure 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DOVATO
  • ViiV Healthcare Company $511
$511 32 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $162
$162 — —
DUPIXENT
  • GENZYME CORPORATION $52
  • Regeneron Healthcare Solutions, Inc. $38
$89 — —
CABENUVA
  • ViiV Healthcare Company $84
$84 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

458 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record